These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35205700)

  • 1. Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
    Martorana F; Da Silva LA; Sessa C; Colombo I
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
    Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
    J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
    Mao X; Lee NK; Saad SE; Fong IL
    Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
    Carrassa L; Colombo I; Damia G; Bertoni F
    Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    Yap TA; Plummer R; Azad NS; Helleday T
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
    Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
    Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
    Front Oncol; 2020; 10():581217. PubMed ID: 33224881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation.
    Carlsen L; El-Deiry WS
    Front Oncol; 2022; 12():998388. PubMed ID: 36276148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
    Wang M; Chen S; Ao D
    MedComm (2020); 2021 Dec; 2(4):654-691. PubMed ID: 34977872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
    Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
    Front Oncol; 2021; 11():648687. PubMed ID: 34026622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the DNA damage response in hematological malignancies.
    De Mel S; Lee AR; Tan JHI; Tan RZY; Poon LM; Chan E; Lee J; Chee YL; Lakshminarasappa SR; Jaynes PW; Jeyasekharan AD
    Front Oncol; 2024; 14():1307839. PubMed ID: 38347838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
    Bahena-González A; Toledo-Leyva A; Gallardo-Rincón D
    Chin Clin Oncol; 2020 Aug; 9(4):51. PubMed ID: 32819110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA damage response in breast cancer and its significant role in guiding novel precise therapies.
    Li J; Jia Z; Dong L; Cao H; Huang Y; Xu H; Xie Z; Jiang Y; Wang X; Liu J
    Biomark Res; 2024 Sep; 12(1):111. PubMed ID: 39334297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer.
    Bouberhan S; Bar-Peled L; Matoba Y; Mazina V; Philp L; Rueda BR
    Cancer Drug Resist; 2023; 6(2):345-357. PubMed ID: 37457127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.